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22 :4 546AbstractType2diabetes (T2D)hasbeen suggested tobea risk factor formultiplemyeloma (MM),but the
relationship between the two traits is still not well understood. The aims of this study were to
evaluatewhether 58genome-wide-association-studies (GWAS)-identified commonvariants for
T2D influence the risk of developing MM and to determine whether predictive models built
with these variants might help to predict the disease risk. We conducted a case–control
study including 1420 MM patients and 1858 controls ascertained through the International
Multiple Myeloma (IMMEnSE) consortium. Subjects carrying the KCNQ1rs2237892T allele or the
CDKN2A-2Brs2383208G/G, IGF1rs35767T/T andMADDrs7944584T/T genotypes had a significantly
increased risk of MM (odds ratio (OR)Z1.32–2.13) whereas those carrying the KCNJ11rs5215C,
KCNJ11rs5219T and THADArs7578597C alleles or the FTOrs8050136A/A and LTArs1041981C/C genotypes
showeda significantlydecreased riskofdeveloping thedisease (ORZ0.76–0.85). Interestingly, a
predictionmodel including those T2D-related variants associatedwith the risk ofMMshoweda
significantly improved discriminatory ability to predict the disease when compared to a model
without genetic information (area under the curve (AUC)Z0.645 vs AUCZ0.629; PZ4.05!
10K06). A gender-stratified analysis also revealed a significant gender effect modification for
ADAM30rs2641348 and NOTCH2rs10923931 variants (PinteractionZ0.001 and 0.0004, respectively).
Men carrying theADAM30rs2641348C andNOTCH2rs10923931Talleles had a significantly decreased
risk ofMMwhereas an opposite but not significant effect was observed in women (ORMZ0.71
and ORMZ0.66 vs ORWZ1.22 and ORWZ1.15, respectively). These results suggest that
TD2-related variantsmay influence the risk ofdevelopingMMand their genotypingmight help
to improve MM risk prediction models.http://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0029 Printed in Great Britain
Published by Bioscientifica Ltd.Key Words
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(2015) 22, 545–559IntroductionMultiple myeloma (MM) is a plasma-cell neoplasm of
complex aetiology that may arise as a result of the
interaction between adverse environmental and inherited
genetic risk factors (Morgan et al. 2012). Although survival
rates forMMhave improveddramaticallyduring the last two
decades, likely due to the introduction of novel targeted
therapies (proteasome inhibitors, immunomodulators and
others), the disease outcome still remains poorwith a 5-year
overall survival ratenothigher than55%(Kumar etal. 2014).
Age, male gender, African ancestry and monoclonal
gammopathy of uncertain significance (MGUS) have been
established as major risk factors for MM (Alexander et al.
2007). In addition, exposure to a wide range of toxins
as well as type 2 diabetes (T2D) and obesity have been
suggested as importantmediators of the complexprocess of
myelomagenesis (Alexander et al. 2007, Lope et al. 2008,
Wallin & Larsson 2011). Among these latter preventable
factors, T2D has attracted significant attention since it has
been consistently identified as a medical condition
frequently found in MM patients (Khan et al. 2008,
Richardson et al. 2009, Castillo et al. 2012) and it is thought
to influence the myelomagenesis through hyperglycaemiaand insulin-dependent and -independentmechanisms (Xu
et al. 2014). In a recentwell-poweredmeta-analysis,Castillo
et al. (2012) observed that T2D was significantly associated
with an increased risk of developing the disease (Castillo
et al. 2012). This finding concurs with those previously
reported in several epidemiological studies that showed
a high incidence of T2D among MM patients ranging
between 11 and 22% (Richardson et al. 2006, Badros et al.
2007). In addition, it has been reported that T2Dmay have
a negative impact on MM prognosis (Chiu et al. 2006,
Wu et al. 2014) and that the treatment with anti-diabetic
drugs may effectively kill MM cells (Wu et al. 2014).
Considering that T2D and MM have strong genetic
components and share several biological pathways and
markers (Xu et al. 2014) and that T2D-related polymorph-
isms may influence the risk of developing solid cancer
(Folsom et al. 2008, Cheng et al. 2011, Sainz et al. 2012,
Ma et al. 2014), we hypothesized that genetic risk factors
for T2Dmay be associated with the risk of developing MM.
So far there have not been studies evaluating the impact
of diabetogenic variants on the risk of developing
hematological cancers. Therefore, we decided to conduct a
E
n
d
o
cr
in
e
-R
e
la
te
d
C
a
n
ce
r
Research R Rı´os, C B Lupian˜ez et al. Type 2 diabetes-related
polymorphisms and multiple
myeloma risk
22 :4 547multi-centre case–control study including 1420 MM
patients and 1858 controls to evaluate whether 58 variants
convincingly shown to be associatedwithT2Dcontribute to
the risk of developing MM. We also aimed at determining
whether predictive models including T2D-related variants
significantly improve the discriminatory ability to predict
the risk of MM.Material and methods
Study population
The study population consisted of 1420 MM patients (705
women and 715 men) and 1858 controls (916 women and
942 men) ascertained through the International Multiple
Myeloma (IMMEnSE) consortium (Supplementary Table 1,
see section on supplementary data given at the end of this
article), which has been described in detail elsewhere
(Martino et al. 2012). The diagnosis of MM was assigned
by physician and fulfilled the International Myeloma
Working Group (IMWG) criteria (International Myeloma
Working Group 2003). Controls were blood donors or
hospitalized subjects with a diagnosis not related to cancer
who were recruited in the same geographical area of the
cases (Supplementary Table 1). Additional information
concerning to the recruitment strategy of controls is
shown in the Supplementary Material. The investigation
was approved by the ethical committee of each participant
institution, functioning according to the third edition of
the Guidelines on the Practice of Ethical Committees in
Medical Research issued by the Royal College of Physicians
ofLondon (www.rcplondon.ac.uk) andall participants gave
their written informed consent to participate in the study.SNP selection and genotyping
Fifty-eight genome-wide-association-studies (GWAS)-ident-
ified variants for T2D were selected to be genotyped in the
IMMEnSE consortium population (Table 1 and Supple-
mentary Material). The genotyping of the selected poly-
morphismswas carried out atGENYO (Centre forGenomics
and Oncological Research: Pfizer/University of Granada/
Andalusian Regional Government, Granada, Spain) using
KASPar assays (LGC Genomics, Hoddesdon, UK) according
tomanufacturer’s instructions. For internal quality control,
5% of samples were randomly selected and included as
duplicates. Concordance between the original and the
duplicate samples for the 58 SNPs was R99.0%. Call rates
for all SNPs were R90.0% with the exception of the
WFS1rs734312 SNP that was excluded from further analyses.http://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0029 Printed in Great BritainStatistical analysis
The Hardy–Weinberg Equilibrium (HWE) tests were
performed in the control group by a standard observed-
expected c2 test. Logistic regression analyses were used to
assess the effects of the genetic polymorphisms onMM risk
using co-dominant, dominant, recessive and log-additive
inheritance models. Overall analyses were adjusted for age
at diagnosis, gender and country of origin. All analyses
were conducted using the statistical software SSPS (version
20.0). Statistical power was calculated using the Quanto
vs12.4 (http://biostats.usc.edu/software) assuming a log-
additive model.
In order to account for multiple testing, we calculated
an adjusted significance level using the Meff method
(Nyholt 2004), which considers the number of indepen-
dent marker loci (MeffLiZ55) but also the number of
models of inheritance tested (co-dominant, dominant,
recessive and log-additive). Thus, the resulting threshold
for the main effect analysis was 0.00022 ((0.05/55)/4)
(Supplementary Material). Since a study-wide significance
threshold considering all these factors is generally
perceived as a ‘too conservative’ test, we also assessed the
magnitude of observed associations between selected SNPs
and risk of MM through a quantile–quantile (QQ) plot
generated from the results of the IMMEnSE population.
The observed association P values were ranked in order
from smallest to largest on the y-axis and plotted against
the expected results from a theoretical wc2-distribution
under the null hypothesis of no association on the x-axis.
A deviation from the identity line would confirm that the
number of corresponding associations is more than
expected under the null hypothesis and therefore that
these associations are likely to be true associations.Predictive models and discriminative accuracy
We also examined the value of T2D-related polymorph-
isms for prediction of MM using stepwise logistic and Cox
regression analyses. We built a predictionmodel including
age and sex and those genetic variants that showed
significant associations with MM in the single-SNP
analysis (P!0.05). Then, using P values as a selection
criterion, we dropped variables that have the highest
P value and we stopped when all variables were significant
defined by P!0.10. The area under the curve (AUC) of a
receiver operating characteristic (ROC) curve analysis was
used to assess the discriminative accuracy of this particular
model compared with a reference model including age
and sex as covariates. A K2log likelihood ratio (LR) testPublished by Bioscientifica Ltd.
Table 1 Selected type-2 diabetes-related SNPs
Gene name dbSNP rs#
Nucleotide
substitution
Reference
allele
IMMEnSE
GWAS-
identified risk
allele for T2D
Location/Aa
substitution References
ADAM30 rs2641348 T/Ca T C L359P Zeggini et al. (2008) and
Lyssenko et al. (2009)
ADAMTS9 rs4607103 T/C C C Near gene Mohlke et al. (2008), Zeggini et al. (2008)
and Shu et al. (2010)
ADCY5 rs11708067 T/C T T Intronic Dupuis et al. (2010) and
Saxena et al. (2010)
ADRA2A rs10885122 G/T G G Near
ADRA2A
Dupuis et al. (2010)
ARAPI,
CENTD2
rs1552224 G/T T A Near gene Voight et al. (2010) and
Nielsen et al. (2011)
BCL11A rs10490072 C/T T T Near gene Zeggini et al. (2008)
CDC123 rs12779790 A/G A G Near gene Mohlke et al. (2008), Zeggini et al. (2008)
and Shu et al. (2010)
CDKAL1 rs7754840 C/G G C Intronic Diabetes Genetics Initiative of Broad
Institute of Harvard and MIT, Lund
University, and Novartis Institutes of
BioMedical Research et al. (2007),
Florez et al. (2007) and
Scott et al. (2007)
CDKN2A-2B rs564398 T/C T T Near gene Diabetes Genetics Initiative of Broad
Institute of Harvard and MIT, Lund
University, and Novartis Institutes of
BioMedical Research et al. (2007),
Scott et al. (2007), Mohlke et al. (2008),
Zeggini et al. (2008), Takeuchi et al.
(2009), Shu et al. (2010) and Yamauchi
et al. (2010)
CDKN2A-2B rs10811661 T/C T T Near gene
CDKN2A-2B rs2383208 A/Gb A A Near gene
COL5A1 rs4240702 C/T C NS Intronic Bouatia-Naji et al. (2009)
CRY2 rs11605924 A/C C A Intronic Dupuis et al. (2010)
DCD rs1153188 A/T A A Near gene Zeggini et al. (2008)
EXT2 rs1113132 C/G C C Intronic Florez et al. (2007) and Sladek et al. (2007)
FADS1 rs174550 C/T A T Intronic Dupuis et al. (2010)
FAM148B rs11071657 A/G A A Near gene Chambers et al. (2008) and
Dupuis et al. (2010)
FLJ39370 rs17044137 A/T T A Near gene Diabetes Genetics Initiative of Broad
Institute of Harvard and MIT, Lund
University, and Novartis Institutes of
BioMedical Research et al. (2007)
FTO rs8050136 A/Cc C A Intronic Wellcome Trust Case Control (2007),
Zeggini et al. (2007) and Mohlke et al.
(2008)
G6PC2 rs560887 G/A G G Intronic Bouatia-Naji et al. (2008, 2009), Chen
et al. (2008), Prokopenko et al. (2009)
and Dupuis et al. (2010)
GCK rs1799884 G/A G A Near gene Bouatia-Naji et al. (2008, 2009), Chen
et al. (2008), Prokopenko et al. (2009)
and Dupuis et al. (2010)
GCKR rs1260326 C/T C T L445P Bouatia-Naji et al. (2009), Dupuis et al.
(2010) and Saxena et al. (2010)
HHEX rs1111875 G/A C C Near gene Diabetes Genetics Initiative of Broad
Institute of Harvard and MIT, Lund
University, and Novartis Institutes of
BioMedical Research et al. (2007),
Florez et al. (2007), Scott et al. (2007),
Sladek et al. (2007), Wellcome Trust
Case Control (2007), Zeggini et al.
(2007) and Mohlke et al. (2008)
HMGA2 rs1531343 C/G G C Near gene Voight et al. (2010) and
Nielsen et al. (2011)
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Table 1 Continued
Gene name dbSNP rs#
Nucleotide
substitution
Reference
allele
IMMEnSE
GWAS-
identified risk
allele for T2D
Location/Aa
substitution References
HNF1A, TCF1 rs7957197 A/T T T Intronic Voight et al. (2010) and
Nielsen et al. (2011)
IGF1 rs35767 C/Td C C Near gene Pechlivanis et al. (2007) and
Dupuis et al. (2010)
IGF2BP2 rs4402960 G/T C T Intronic Diabetes Genetics Initiative of Broad
Institute of Harvard and MIT, Lund
University, and Novartis Institutes of
BioMedical Research et al. (2007),
Florez et al. (2007), Scott et al. (2007),
Wellcome Trust Case Control (2007),
Zeggini et al. (2007), Mohlke et al.
(2008) and Shu et al. (2010)
IL13 rs20541 C/T C T R144Q Diabetes Genetics Initiative of Broad
Institute of Harvard and MIT, Lund
University, and Novartis Institutes of
BioMedical Research et al. (2007)
IRS1 rs2943641 C/T C C Near gene Rung et al. (2009), Voight et al. (2010) and
Tang et al. (2013)
JAZF1 rs864745 A/G A T Intronic Zeggini et al. (2008) and Shu et al. (2010)
KCNJ11 rs5215 T/Ce T C V337I Gloyn et al. (2003), Diabetes Genetics
Initiative of Broad Institute of Harvard
and MIT, Lund University, and Novartis
Institutes of BioMedical Research et al.
(2007), Scott et al. (2007), Wellcome
Trust Case Control (2007), Zeggini et al.
(2007), Willer et al. (2007) and Mohlke
et al. (2008)
KCNJ11 rs5219 C/Tf C T K23E
KCNQ1 rs2237897 C/T T C Intronic Unoki et al. (2008), Yasuda et al. (2008),
Tsai et al. (2010) and Yamauchi et al.
(2010)
KCNQ1 rs2074196 G/T G G Intronic
KCNQ1 rs2237892 C/Tg C C Intronic
KCNQ1 rs2237895 A/C A C Intronic
KCNQ1OT1 rs231362 C/T C G Intronic Tsai et al. (2010), Voight et al. (2010) and
Nielsen et al. (2011)
LTA rs1041981 A/Ce A A T60N Hamid et al. (2005)
MADD rs7944584 A/Td A A Intronic Dupuis et al. (2010)
MCR4 rs12970134 A/G G A Near gene Chambers et al. (2008)
MTNR1B rs1387153 C/T C T Near gene Bouatia-Naji et al. (2009), Prokopenko
et al. (2009) and Voight et al. (2010)
NOTCH2 rs10923931 G/Th G T Intronic Mohlke et al. (2008) and
Zeggini et al. (2008)
PKN2 rs6698181 C/T C T Intergenic Diabetes Genetics Initiative of Broad
Institute of Harvard and MIT, Lund
University, and Novartis Institutes of
BioMedical Research et al. (2007)
PPARG rs1801282 C/G C C P12A Altshuler et al. (2000), Diabetes Genetics
Initiative of Broad Institute of Harvard
and MIT, Lund University, and Novartis
Institutes of BioMedical Research et al.
(2007), Scott et al. (2007), Wellcome
Trust Case Control (2007), Willer et al.
(2007), Zeggini et al. (2007, 2008) and
Mohlke et al. (2008)
PRC1 rs8042680 A/C C A Intronic Voight et al. (2010) and
Nielsen et al. (2011)
PROX1 rs340874 A/G A G Promoter Dupuis et al. (2010)
RBMS1 rs7593730 C/T C T Intronic Qi et al. (2010)
SLC2A2 rs11920090 A/T A T Intronic Dupuis et al. (2010)
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Table 1 Continued
Gene name dbSNP rs#
Nucleotide
substitution
Reference
allele
IMMEnSE
GWAS-
identified risk
allele for T2D
Location/Aa
substitution References
SLC30A8 rs13266634 C/T C C R325W Diabetes Genetics Initiative of Broad
Institute of Harvard and MIT, Lund
University, and Novartis Institutes of
BioMedical Research et al. (2007),
Florez et al. (2007), Scott et al. (2007),
Sladek et al. (2007), Steinthorsdottir
et al. (2007), Wellcome Trust Case
Control (2007), Zeggini et al. (2007),
Mohlke et al. (2008), Dupuis et al.
(2010) and Shu et al. (2010)
TCF2 rs7501939 C/T C C Intronic Gudmundsson et al. (2007) and Sandhu
et al. (2007)
TCF7L2 rs7903146 C/T C T Intronic Grant et al. (2006), Scott et al. (2006),
Diabetes Genetics Initiative of Broad
Institute of Harvard and MIT, Lund
University, and Novartis Institutes of
BioMedical Research et al. (2007),
Florez et al. (2007), Scott et al. (2007),
Sladek et al. (2007), Steinthorsdottir
et al. (2007), Wellcome Trust Case
Control (2007), Zeggini et al. (2007),
Mohlke et al. (2008), Dupuis et al.
(2010) and Saxena et al. (2010)
TCF7L2 rs12255372 G/T G T Intronic
THADA rs7578597 T/Ce T T T1187A Zeggini et al. (2008)
TP53INP1 rs896854 A/G G G Intronic Voight et al. (2010) and
Nielsen et al. (2011)
TSPAN8 rs7961581 C/T T C Near gene Grarup et al. (2008)
VEGFA rs9472138 C/T C T Near gene Zeggini et al. (2008)
WFS1 rs734312 A/G A NS H611R Sandhu et al. (2007)
WFS1 rs10010131 A/G G G Intronic Sandhu et al. (2007)
NS, not specified; Aa, aminoacid; GWAS, genome-wide association studies. Effect allele in bold and underlined.
aC allele was associated with a decreased risk of MM in men whereas an opposite effect was detected in women.
bG allele was associated with an increased risk of developing MM.
cA/A genotype was associated with a decreased risk of MM (recessive model).
dT/T genotype was associated with a decreased risk of MM (recessive model).
eC allele was associated with a decreased risk of MM.
fT allele was associated with an decreased risk of MM.
gT allele was associated with an increased risk of MM.
hT allele was associated with a decreased risk of MM in men whereas an opposite effect was detected in women.
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22 :4 550was used to determine whether the predictive model
including genetic information fitted significantly better
the data compared to the reference model. Although the
addition of genetic variables to the reference model will
almost always make the model fit better, the LR test
allowed us to confirm whether the difference in model fit
between both models was statistically significant. Besides
this suggestive analysis, we also ran a randomization test
to confirm whether the improved predictive ability of the
model including genetic variants significantly associated
with MM was consistent after 10 000 iterations. We
compared our full predictive model including significant
SNPs, age and gender (‘original’ model) with 10 000
‘randomized’ models in which the effect of SNPs on MM
risk was neutralized by reassigning randomly all genotypeshttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0029 Printed in Great Britain(null distribution; Supplementary Material). Sub-
sequently, we calculated an empirical Piterations-value by
dividing the number of times in which the ‘randomized’
AUC value was equal or greater than the ‘original’ AUC
value by the number of iterations. Then, we could also
calculate the Z score and PZ score-value for the original AUC
using the ‘randomized’ AUC average of these 10 000
iterations and their S.D. All analyses were performed
using R software (http://www.r-project.org/).Gender-specific association analysis
We also evaluate gender-specific associations of selected
SNPs with MM risk. Logistic regression analyses were
corrected for age and country of origin. Of note, toPublished by Bioscientifica Ltd.
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22 :4 551evaluate whether a different gender distribution across
populations within the IMMEnSE consortium could be
responsible for the gender effect modification observed
for certain SNPs, we also assessed heterogeneity and index
I2 statistic using Cochran’s c2 based Q statistic test
(Lau et al. 1997). Heterogeneity was considered significant
when P!0.1.Results
Overall associations of selected SNPs with MM risk
All SNPs were in HWE (PO0.001) with the exception of the
COL5A1rs4240702, which was therefore excluded from the
statistical analyses. Logistic regression analysis showed
that carriers of the KCNQ1rs2237892T allele or the CDKN2A-
2Brs2383208G/G, IGF1rs35767T/T and MADDrs7944584T/T geno-
types had an increased risk of MM (odds ratio (OR)Z1.32,
95% CI 1.01–1.71, PZ0.039; ORZ1.86, 95% CI 1.12–3.11,
PZ0.016; ORZ2.13, 95% CI 1.35–3.37, PZ0.0012 and
ORZ1.33, 95% CI 1.06–1.67, PZ0.014, respectively)
whereas those harbouring the KCNJ11rs5215C,
KCNJ11rs5219T and THADArs7578597C alleles or the
FTOrs8050136A/A and LTArs1041981C/C genotypes showed a
decreased risk for the disease (ORZ0.85, 95% CI 0.73–
0.99, PZ0.038; ORZ0.84, 95% CI 0.72–0.99, PZ0.034;
ORZ0.81, 95% CI 0.68–0.98, PZ0.032; ORZ0.78, 95% CI
0.64–0.95, PZ0.013 and ORZ0.76, 95% CI 0.58–0.99,
PZ0.042, respectively; Table 2). When we corrected for
multiple testing (with a threshold of PZ0.00022), none
of the reported associations remained statistically
significant. The strongest association observed was for
the IGF1rs35767 SNP with an increased risk of developing
MM (ORZ2.13, 95% CI 1.35–3.37, PZ0.0012). In spite of
these results, the QQ plot showed an early deviation of
identity line, which suggested a high proportion of true
associations for a given P value (Fig. 1). Therefore, the data
suggest that the effect attributed to SNPs in T2D-related
loci (FTO, MADD, CDKN2A-2B, LTA) might represent
true associations.Predictive value of T2D-related variants
In order to determine whether there was a joint effect of
SNPs significantly associated with MM, we built a
prediction model including gender and those nine SNPs
showing overall significant associations with MM. After
excluding the variables that did not remain significant in
the model, the final model included six SNPs that
increased the discriminatory ability to predict the risk ofhttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0029 Printed in Great BritainMM when compared with a reference model including
age and gender as covariates (AUCZ0.645 95% CI
0.624–0.666; Table 3). The LR test showed that the
model including genetic variants fitted better the data
than the referencemodel, and that the difference inmodel
fit between both models was statistically significant
(PZ4.05!10K06). In addition, when we evaluated
whether the model including genetic variants was
consistent in predicting better the MM risk, we found
that it showed an AUC value systematically higher than
those of the 10 000 randomized models (null distribution;
Z scoreZ6.42, PZ6.81!10K11; Supplementary Material),
emphasizing the importance of considering genetic
variants significantly associated with MM when building
predictive models.Gender-specific associations with MM risk
Interestingly, a gender-stratified analysis also
revealed significant gender effect modifications for
ADAM30rs2641348 and NOTCH2rs10923931 SNPs (Pinteraction
Z0.001 and 0.0004 respectively). For ADAM30rs2641348C
and NOTCH2rs10923931T alleles, a significantly reduced risk
for the disease was observed in men (per-allele ORZ0.71,
95% CI 0.54–0.94, PZ0.015 and per-allele ORZ0.66, 95%
CI 0.50–0.86, PZ0.0019, respectively) whereas a non-
significant opposite effect was seen in women (per-allele
ORZ1.22, 95% CI 0.93–1.60 and per-allele ORZ1.15, 95%
CI 0.89–1.50 respectively). A statistically significant
heterogeneity, considering P!0.05 as a threshold, was
also confirmed for these two SNPs (PHETZ0.0039 and
I2Z87.99% and PHETZ0.0024 and I
2Z89.12%, respect-
ively), which supports the notion suggesting a role
of gender in modulating the effect of these SNPs on
MM risk. Although there was not a significant
interaction with gender, we observed additional gender-
specific associations for WFS1rs10010131, THADArs7578597,
EXT2rs1113132 and GCKrs1799884 SNPs according to
dominant or recessive models of inheritance (Table 2
and Supplementary Material).
When we took account of multiple testing (with a
threshold of PZ0.00022), we found that the effect of the
IGF1rs35767 variant was stronger in women than men with
an association approaching significance with an increased
risk of developing MM (ORZ3.13, 95% CI 1.46–6.71,
PZ0.0026 vs ORZ1.69, 95% CI 0.94–3.02, PZ0.079
respectively). In addition, we found that the association
of NOTCH2rs10923931 SNP with a decreased risk of MM
in men was close to significance according to dominant
and log-additive models (ORZ0.66, 95% CI 0.50–0.86,Published by Bioscientifica Ltd.
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DOI: 10.1530/ERC-15-0029 Printed in Great BritainPZ0.0019 and PtrendZ0.0007), which may suggest a
gender-specific allele-dosage effect for this variant to
modulate the disease risk (PinteractionZ0.0004; Table 2).
According to a log-additive model, we also found that
the association of the ADAM30rs2641348C allele with a
decreased risk of MM in men showed a slight trend to be
significant considering multiple testing (ORZ0.71, 95%
CI 0.55–0.92, PZ0.0072) whereas, according to a recessive
model, the association of the ADAM30rs2641348C/C geno-
type was also close to survive multiple testing correction
(ORZ4.40, 95% CI 1.44–13.40, PZ0.00059; Table 2 and
Supplementary Table 2, see section on supplementary data
given at the end of this article).Discussion
In the present study, we report for the first time evidence of
significant associations between GWAS-identified
T2D genetic variants and MM risk. We found that carriers
of the KCNQ1rs2237892T allele, CDKN2A-2Brs2383208G/G,
IGF1rs35767T/T and MADDrs7944584T/T genotypes were at
increased risk of MM, whereas those carrying the
KCNJ11rs5215C, KCNJ11rs5219T and THADArs7578597C alleles
or the FTOrs8050136A/A and LTArs1041981C/C genotypes
showed a decreased risk for the disease. The associations
for the KCNQ1, CDKN2A-2B, IGF1, MADD, KCNJ11, and
THADA gene variants with the risk of MM showed an
opposite direction to those previously reported in the
GWAS for T2D (i.e., the risk allele was the opposite for MM
and T2DM), which points towards a non-diabetogenic
mechanism underlying the effect of these variants to
modulate the risk of the disease. In support of this
hypothesis, several studies have suggested that, besides
their influence on pancreatic function and insulin
secretion through awide variety of biologicalmechanisms,
some of these genes may also act as tumour suppressor
genes (Koh et al. 1995, Kim & Sharpless 2006, Than et al.
2013) andhave an impact in themodulationof cell survival
(Butt et al. 1999, Ortega et al. 2002, Sharifi et al. 2013),
differentiation (Pancewicz et al. 2010), proliferation
(Grimberg 2003, Pancewicz et al. 2010) and apoptosis
(LeRoith et al. 1995, Li et al. 2008, Pancewicz et al. 2010).
Interestingly, a recent study demonstrated that T2D status
was not implicated in the relationship betweenHNF1B and
JAZF1 variants andprostate cancer risk (Stevens et al. 2010),
which is in line with our hypothesis suggesting that T2D-
related variants may determine the risk of MM through
non-diabetogenic mechanisms.
When we took into account multiple testing correc-
tions, only the association of the IGF1rs35767 promoterPublished by Bioscientifica Ltd.
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Figure 1
QQ plot used to evaluate the magnitude of observed associations of
T2D-related variants with risk of MM. QQ plot was calculated assuming a
recessive model of inheritance. Deviation from the expected distribution is
observed above an expected X2 of 0.75. The x-axis is -log10 of the expected
P values (under a null hypothesis of no effects) whereas the y-axis is -log10
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remained close to significance (PZ0.0012), which
suggested that the IGF1 locus may play an important
role in triggering cell proliferation in malignant plasma
cells. In support of the hypothesis, it has been observed
that IGF1 acts as a major growth factor in MM that,
directly or in cooperation with other growth factors,
induces MM cell growth and proliferation (Ferlin et al.
2000, Bommert et al. 2006, Sprynski et al. 2009) and canTable 3 Discriminative value AUC for models including T2D-relate
SNPs P value
Reference modelc
Gender 0.731
Age !2.00!10K16
Predictive model built with six significant SNPsd
IGF1rs35767 0.004
FTOrs8050136 0.002
MADDrs7944584 0.094
PRC1rs8042680 0.061
KCNJ11rs5215 0.027
KCNQ1rs2237892 0.008
Gender 0.776
Age !2.00!10K16
aIncluding age and gender as variables never dropped from models.
bCompared with a baseline model with AUCZ0.5.
cIncluding age and gender as covariates.
dSNPs showing a significant association with MM (P!0.05). After removing mi
eA LR test showed that the model including genetic variants fitted the data bet
both models was statistically significant (K2log likelihood ratio test, dfZ6, PZ4
(significant SNPs model): 3345.2.
fA sort analysis revealed that this model showed an AUC value systematically h
Z scoreZ6.42, PZ6.81!10K11; Supplementary Material).
http://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0029 Printed in Great Britaineventually lead to chemoresistance (Xu et al. 1997, Kuhn
et al. 2012). Likewise, it has been also reported that
treatment with metformin, an anti-diabetic drug that
inhibits IGF1 signaling pathway, significantly reduces the
risk of transformation from MGUS to symptomatic MM
(American Society of Clinical Oncology Annual Meeting
2014; abstract 1532) and that constant use of this
treatment may induce cell apoptosis (Rattan et al. 2012)
and enhance the effectiveness of chemotherapeutic
regimes in blood and solid cancers (Feng et al. 2011, Pan
et al. 2012, Watson 2013). Interestingly, several authors
have also reported that IGF1 and its analogues are
associated with an increased death in patients with
progressive MM (Standal et al. 2002, Chou et al. 2012,
Wu et al. 2014), whereas the administration of metformin
results in the reduction of deaths in patients with
progressive disease (Wu et al. 2014).
In fact, Chen et al. (2013) recently demonstrated that
the IGF1rs35767 SNP together with two neighbour SNPs
constitutes a haplotype that efficiently regulates transcrip-
tional activity (Chen et al. 2013). Similarly, several studies
have consistently reported that carriers of the IGF1rs35767T
allele showed significantly higher levels of circulating
IGF1 than those harbouring the WT allele (Mannino et al.
2013, Sesti et al. 2014) and that the presence of this variant
is associated with an increased risk of developing several
types of cancer (Ollberding et al. 2012, Qian et al. 2014).
Although it is tempting to speculate that the
IGF1rs35767 SNPmay be responsible for the effect attributed
to diabetes on the risk of MM, we believe that rather thand variants
OR 95% CI AUC 95% CIab
0.972 (0.828–1.141)
1.036 (1.030–1.042) 0.629 (0.607–0.650)e
2.076 (1.258–3.426)
0.723 (0.586–0.892)
1.218 (0.967–1.535)
1.261 (0.989–1.607)
0.832 (0.706–0.980)
1.468 (1.106–1.950)
1.024 (0.871–1.204)
1.037 (1.031–1.043) 0.645 (0.624–0.666)ef
ssing values, 2460 subjects were available for prediction capacity analysis.
ter than the reference model and that the difference in model fit between
.05!10K06). residual deviance (reference model): 3380.4. residual deviance
igher than those observed in 10 000 randomized models (null distribution;
Published by Bioscientifica Ltd.
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22 :4 555acting separately to modulate the risk of the disease, this
genetic variant acts along with additional variants within
KCNQ1, CDKN2A-2B, MADD, KCNJ11, THADA, LTA and
FTO genes tomodulate the disease risk. In order to test this
hypothesis, we decided to evaluate the predictive value of
T2D-related polymorphisms for prediction of MM using
stepwise logistic andCox regressionanalyses. Interestingly,
we found that adding genetic factors to a model without
covariates (including only age and gender) substantially
improved the prediction of disease development.
A predictive model including six SNPs significantly associ-
ated with MM in the single analysis showed an adjusted
concordance statistic AUC of 64.5% for MM. The consist-
ency of this result was confirmed through a randomization
test that showedthatnoneof the10 000randomizedmodels
showed a higher AUC value than our ‘original’ model
including six genetic variants, age and gender. The addition
of genetic variants associated with MM at P!0.10 level did
not improve the discriminatory ability to predict MM,
which pointed towards a joint contribution of IGF1, FTO,
MADD, PRC1, KCNJ11 and KCNQ1 polymorphisms
to predict the risk of the disease. Although the prediction
capacity of these models could be considered relatively
small when compared with a reference model, the relative
absence of current diagnostic factors for MM suggest that
theuseofgenetic variants couldbeagoodoptionto improve
the prediction of the disease risk.
The association of the non-diabetogenic alleles or
genotypes for the polymorphisms within KCNQ1,
CDKN2A-2B, MADD, KCNJ11, THADA and FTO genes
with the risk of MM suggests that these genes, rather than
acting through an insulin-dependent mechanism, may
modulate the risk of MM by acting as tumour suppressor
genes (Duro et al. 1995) or throughmechanisms promoting
cancer cell apoptosis (Rippe et al. 2003, Turner et al. 2013).
In support of this idea, it has been recently reported that
most of these genes are highly expressed in tumours and
that geneticpolymorphisms in these loci are also associated
with cancer development (Sauroja et al. 2000, Cander et al.
2014) and tumour progression (Chen et al. 2009).
The association of LTArs1041981 SNP with a decreased
risk of MM showed a similar direction to that observed in
the GWAS for T2D (LTArs1041981A as risk allele) suggests a
diabetogenic effect of this SNP to modify the risk of MM.
However, we could not dismiss the idea suggesting that
observed association could be due to a different distri-
bution of diabetics between MM cases and controls.
Similarly, although the direction of the association for
the FTOrs8050136 SNP with the risk of MM was opposite to
the one observed in the GWAS for T2D, we could not rulehttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0029 Printed in Great Britainout the possibility that the observed effect for this
obesogenic SNP (Scuteri et al. 2007) could be due to
significant differences in BMI between MM cases and
controls. Further studies using well-characterized cohorts
are needed to confirm these latter associations.
Although it was not the primary objective of this study,
we also performed gender-stratified analysis to assess
whether there was a gender effect modification of selected
SNPs tomodulate the risk of developingMM. Interestingly,
we found a significant gender effect modification for
ADAM30rs2641348, and NOTCH2rs10923931 SNPs, which
suggested a gender-specific effect of these loci to modulate
the risk of MM. We observed that, according to a log-
additive model of inheritance, the association of the
NOTCH2rs10923931 SNP with a decreased risk of MM in men
and the association of ADAM30rs2641348C/C genotype with
an increased risk of MM inwomen showed amarginal level
of significance after correction for multiple testing.
Recently, it has been demonstrated that NOTCH2 is highly
expressed in MM cells and that it is a key regulator of MM
pathogenesis (Colombo et al. 2013). In particular, it has
been reported that the activation of the NOTCH2, which
interacts with Wnt components, induces an exacerbated
growthofMMcells andaccelerated the course of the disease
by promoting cancer stem cell self-renewal (Xu et al. 2012a)
and resistance tochemotherapeutic agents (Xu et al. 2012b).
Considering that NOTCH2rs10923931 and ADAM30rs2641348
are neighbour SNPs in strong linkage disequilibrium
(Zeggini et al. 2008) and that they showed gender-specific
associations with the risk of MM, we hypothesize that
NOTCH2-ADAM30 might represent a gender-specific
susceptibility region for MM. In support of this idea, it has
been reported that gender-specific variants within NOTCH
and WNT signalling pathways, which are involved in
determining cell proliferation and differentiation, may
lead to important gender-specific differences in tumour
recurrence and chemoresistance (Paez et al. 2014).
Our study has both strengths and weaknesses. The
major strength is the large sample size. To our knowledge,
this is the first study to evaluate the overall and gender-
specific associations of T2D-related variants with the risk
of developing MM and to assess their predictive value for
MM. Although the influence of diabetogenic variants on
the risk of the disease was expected to be very modest, our
study was sufficiently powered to detect such small effects.
Based on the genotype frequencies observed in our study
cohort, we had 80% of power (dominant model) to detect
an OR of 1.29 at aZ0.00022 (multiple testing threshold)
for a polymorphism with a minor allele frequency of 0.25.
Although the gender-stratified analysis reduced thePublished by Bioscientifica Ltd.
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of power to detect ORs of 1.43 and 1.44 for men and
women respectively. It is important to realise, however,
that although the present study involves data on over
3334 individuals, the retrospective and multicentre study
design places inevitable limitations on clinical data
availability. T2D status and BMI were not available for a
substantial subset of MM cases, which did not allow us to
adjust our analyses for these variables and, consequently,
to rule out the possibility that some of the reported
associations could arise as a result of a different distri-
bution of diabetics and/or obese subjects between MM
cases and controls. Nonetheless, considering that most of
the reported associations with MM risk showed a different
direction to those previously published in the GWAS for
T2D and given that most of these genes are not linked
to obesity, we could not expect to find false positive
associations due to these confounding factors.
In conclusion, our study indicate that T2D-related
variants within IGF1, KCNJ11, CDKN2A-2B, MADD,
THADA, LTA, FTO, ADAM30 and NOTCH2 genes may
influence the risk of MM through insulin-independent
mechanisms and that genotyping of specific T2D-related
variants may be useful to improve the prediction of MM
development. Additional work is needed to replicate our
findings in independentandwell-characterizedpopulations
and functional studies are also warranted to elucidate the
biological mechanisms underlying the observed effects.Supplementary data
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